Blockchain Co. Launches Digital Coupon Consumer App
Source: Streetwise Reports  (3/8/23)
Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets. More >

New Skin Gene Therapy Gets PDUFA Date
Source: Dr. Joseph Pantginis  (3/1/23)
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report. More >

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment
Source: Streetwise Reports  (2/28/23)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream. More >

AI-Infused Telehealth Platform Absorbs New Patients
Source: Streetwise Reports  (2/22/23)
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients. More >

Biotech Co. Initiates Feasibility Study
Source: Streetwise Reports  (2/9/23)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.  More >

Addiction Therapy Company Secures Major UK Endorsement
Source: Streetwise Reports  (2/7/23)
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region. More >

New Drug for Hearing Loss Approved for Clinical Trials
Source: Dr. Joseph Pantginis  (1/30/23)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report. More >

Biopharma Gains Another Shot on Goal With IND Approval
Source: Edward White   (1/26/23)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report. More >

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus
Source: Streetwise Reports  (1/25/23)
Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus. More >

Med Tech Co. Well-Poised for Revenue Growth This Year
Source: Swayampakula Ramakanth  (1/25/23)
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report. More >

Biopharma Creating COVID Drug Gets US$8.2M From the DOD
Source: Edward White  (1/24/23)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report. More >

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment
Source: Streetwise Reports  (1/24/23)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company. More >

Exploring Why The Economist Named this Biotech 'One To watch' in 2023
Source: Streetwise Reports  (1/23/23)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023. More >

Telehealth Co. Expects More Growth in 2023
Source: Streetwise Reports  (1/20/23)
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program. More >

Biopharma Co.'s Burn Tissue Removal Product Approved
Source: Swayampakula Ramakanth  (1/4/23)
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report. More >

Which Precious Metal Has Chen Excited for 2023?
Source: Streetwise Reports  (12/28/22)
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year? More >

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio
Source: Clive Maund  (12/28/22)
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company. More >

Target Price Boosted 400% on Biopharma Co.
Source: Dr. Joseph Pantginis  (12/27/22)
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report. More >

Biotech at Good Entry Point for Investors, Analyst Says
Source: Andrew Partheniou  (12/20/22)
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report. More >

Data on New Cell Therapy for LBCL Encouraging, Analyst Says
Source: Justin Zelin   (12/16/22)
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report. More >

Why One Fund Owns 13% of This Small-Cap Pharma
Source: Streetwise Reports  (12/12/22)
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
More >

Biotech Co. Signs US$735M Deal
Source: Streetwise Reports  (12/9/22)
Entrada Therapeutics Inc. shares traded 18.5% higher yesterday after the company reported it entered a global development collaboration with Vertex Pharmaceuticals Inc. to develop cutting-edge intracellular Endosomal Escape Vehicle (EEVâ„¢) therapeutics for use in treating myotonic dystrophy type 1. More >

Biopharma Co.'s Shares Triple in Value on US$5B License Deal
Source: Streetwise Reports  (12/7/22)
Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance. More >

Biotech Co.'s Shares Soar to New 52-Week High
Source: Streetwise Reports  (12/7/22)
Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23. More >

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial
Source: Streetwise Reports  (12/5/22)
Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline. More >